Mirati Therapeutics Inc. (MRTX, Financial) President and CEO Charles M. Baum bought 20,000 shares on June 14 at an average price of $7.05 per share. The total transaction amount was $141,000.
Mirati Therapeutics has a market cap of $140.370 million; its shares were traded around $7.05.
Mirati Therapeutics' stock price has decreased from its initial price in 2009 of around $15 per share and also from its peak of a little above $45 per share in 2015.
Mirati Therapeutics has been working on several programs such as MGCD265, MGCD516Â and Mocetinostat. The company reports that its increase in research and development expenses is due to the conduction of these programs as well as third-party development expenses like manufacturing expenses.
GuruFocus has found two severe warning signs for Mirati Therapeutics:
- Low Piotroski F-Score.
- Sloan Ratio of 28.84%.
Recent trades
GuruFocus Guru First Eagle Investment (Trades, Portfolio) kept its position in Mirati Therapeutics unchanged or slightly adjusted.
Braslyn Ltd., 10% owner, bought 468,098 shares of Mirati stock altogether in March, May and June.
Start a free seven-day trial of Premium Membership to GuruFocus.
